RT01 / Nanolattix - LARVOL DELTA

RT01: A first-in-class theranostic radionuclide drug conjugate (RDC) with zirconium-89 and lutetium-177 targeting tissue factor. (ASCO 2026) - "RT01-Zr89 and RT01-177Lu demonstrate outstanding efficacy and safety in preclinical studies as a novel theranostic strategy to overcome resistance in solid tumors. Based on these results, an investigator-initiated clinical trial (IIT) has been initiated."

Cervical Cancer • Lung Cancer • Oncology • Solid Tumor

RT01: A novel anti-TF, radionuclide drug conjugate (RDC) for theranostic precision oncology (AACR 2026) - "Histopathology analysis of ten major organs (kidney, intestine, brain, lung, liver, femur, spleen, stomach, heart, and pancreas) revealed no observable abnormalities or serious toxicity. In conclusion, the RT01 theranostic pair provides superior tumor targeting, rapid non-target clearance, and a favorable toxicity profile, supporting its continued clinical development for TF-positive cancers."

Oncology